Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting

New York, NY, April 20, 2026 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new LX-101 data in Ewing sarcoma has been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting, being held from April 17-22 in San Diego. LX-101 is a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), currently being developed in oncology and autoimmune indications.